Innovative Drug R&D Center

Responsible for the independent incubation of new drug projects and source innovation, ranging from independent project initiation, the screening and discovery of Pre-Clinical Candidate (PCC), to non-clinical development. It has departments such as medicinal chemistry, computer-aided design, synthesis, screening, non-clinical research, and project management. The center is equipped with an AI molecular generation technology platform, collaborates with medicinal chemistry design and innovative synthesis, and has established its own screening and evaluation laboratory systems such as a cell culture room and a Specific Pathogen Free (SPF) animal room, continuously supplying the company with new drug candidate products with differentiated and advantageous characteristics.

Clinical Development Center

Responsible for the clinical development of new drug projects from Investigational New Drug (IND) application to New Drug Application (NDA). It has departments including clinical operation management, clinical medicine, clinical pharmacology, clinical quality assurance, and pharmacovigilance. The team has rich project experience, possesses professional and rigorous capabilities in designing test protocols, and demonstrates efficient and flexible operation execution. It has established good cooperative relationships with nearly a hundred clinical centers across the country. From a medical professional perspective, it jointly evaluates and recommends the developable indications of projects together with the front-end new drug incubation team, maximizing the clinical value of products.

Pharmaceutical R&D Platform

The Pharmaceutical Research Division of Nanjing Vcare, a subsidiary company, is responsible for the pharmaceutical R&D work of new drugs from the confirmation of Pre-Clinical Candidate (PCC) until approval for market launch. It has professional modules such as active pharmaceutical ingredients (APIs), formulations, crystal forms, analysis, quality control, and registration. The R&D team has experience in multiple successful projects, and all modules collaborate closely to conduct screening of crystal forms/salt forms for self-developed innovative drugs, process development, formulation design, quality standard establishment, technical transformation and optimization, and establish a sound pharmaceutical development system to flexibly deal with the variability in the R&D stage of new drugs.

Chemical R&D Platform

The Chemical Division of Nanjing Vcare, a subsidiary company, is responsible for the R&D of starting materials for new drugs from the confirmation of Pre-Clinical Candidate (PCC) until approval for market launch. It has professional modules such as synthesis, analysis, and preparation. The center has an elite chemical team and advanced R&D equipment, and is equipped with high-end technology platforms such as synthetic biology/enzyme catalysis, continuous flow engineering, and photochemistry. It provides starting materials with better quality, more efficient conversion, and greener and more environmentally friendly processes for new drug products, laying the core competitiveness for the cost advantage of new drugs.

Intermediate/API Production Platform

Subsidiary：Tianshu Pharmaceutical,  it has operates a production base spanning 130 mu (approximately 8.67 hectares), comprising two production workshops:operates a production base spanning 130 mu (approximately 8.67 hectares), comprising two production workshops:  The API workshop is equipped with 2 production lines. The advanced pharmaceutical intermediates workshop features 9 production lines.  Collectively, these facilities boast a total reactor volume of 255 cubic meters.  Currently, Tianshu Pharmaceutical has progressively undertaken production tasks for in-house developed innovative drugs, achieving maximized cost efficiency and optimized production cycle performance.  

Drug Formulation Production Platform

The formulation production factory of company is currently in the planning phase, with the objective of achieving fully vertically integrated in-house production — from starting materials to APIs and ultimately finished dosage forms — for its proprietary innovative drugs.